The company has completed all data filings and GDUFA fee payments for 2019 and is waiting for approval from USFDA for the commercial la
The company already filed a complex ANDA in September 2017, targeting Cardiology segment with a market size of $200 million (Rs1,360cr)
Vista Pharmaceuticals informed that the company has submitted an Abbreviated New Drug Application (ANDA) to USFDA on September 25, 2017
Vista Pharmaceuticals edged higher on bourses during Fridays trade on the back of the EIR report issued by USFDA on Thursday.
Per Order for ETF & Mutual Funds Brokerage
Per Order for Delivery, Intraday, F&O, Currency & Commodity